Click here to learn more or to register for the International Symposium on Malignant Mesothelioma.
[youtube=http://www.youtube.com/watch?v=AeaZWg50vKg]
Adding immunotherapy to chemotherapy plus bevacizumab shows promising benefit in survival for non-epitheliod mesothelioma patients, but not across the board
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
